Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01982292 · ClinicalTrials.gov registry record · Phase 2
Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 321
- Enrollment target
NCT01982292: Completed Phase 2 study, sponsored by Novartis Pharmaceuticals.
NCT01982292 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 321 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01982292, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 321 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety of repeat doses of serelaxin in chronic heart failure.
Primary Outcome
A patient is considered antibody positive during the study if he/she had at least two infusions and had at least one evaluable measurement to test for anti-serelaxin antibodies after each infusion and all evaluable antibody test results were positive. A patient is considered antibody negative during the study if he/she had at least two infusions and had at least one evaluable measurement to test for anti-serelaxin antibodies after each infusion and all evaluable antibody test results were negat
Interventions
- DRUG Placebo
- DRUG RLX030 (serelaxin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 321 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-09 |
| Phase | Phase 2 |
What the finished NCT01982292 record still lists
NCT01982292 is an interventional study that assigns participants to a tested intervention. The registered 321 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (141% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01982292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01982292 about?
NCT01982292 is a clinical study titled "Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure". The purpose of this study was to assess the safety of repeat doses of serelaxin in chronic heart failure.
What is the current status of trial NCT01982292?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 321 participants. The study started on 2014-05. Estimated completion is 2015-09.
What interventions are being tested in trial NCT01982292?
The interventions under investigation include: Placebo (DRUG), RLX030 (serelaxin) (DRUG).
Who is sponsoring clinical trial NCT01982292?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01982292's enrollment target sits among peer trials
321 151st of 2000 higher than 1,849 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03715933 · 321 participants · Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- NCT05922878 · 321 participants · Phase 2
Study of ALTO-300 in MDD
- NCT04090359 · 322 participants · Phase 4
Dual Mobility Acetabular Cups in Revision TJA
- NCT04924075 · 322 participants · Phase 2
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia